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a  b  s  t r  a  c  t
Human  papillomaviruses  possess  circular  double  stranded  DNA  genomes  of around  8  kb  in  size from
which  multiple  mRNAs  are  synthesized  during  an  infectious  life  cycle.  Although  at  least  three  viral  pro-
moters  are  used  to initiate  transcription,  viral  mRNAs  are  largely  the  product  of  processing  of  pre-mRNAs
by  alternative  splicing  and polyadenylation.  The  HPV  life  cycle  and  viral  gene  expression  are tightly  linked
to  differentiation  of  the epithelium  the  virus  infects:  there  is  an  orchestrated  production  of  viral  mRNAseywords:
uman papillomavirus
ife cycle
lternative splicing
2
R protein
and  proteins.  In this  review  we describe  viral  mRNA  expression  and  the roles  of  the  SR  and  hnRNP  proteins
that  respectively  positively  and  negatively  regulate  splicing.  We  discuss  HPV  regulation  of  splicing  factors
and  detail  the  evidence  that  the  papillomavirus  E2  protein  has  splicing-related  activities.  We  highlight
the  possibility  that  HPV-mediated  control  of splicing  in differentiating  epithelial  cells  may  be  necessary
to  accomplish  the  viral  replication  cycle.
©  2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
nRNP (http://creativecommons.org/licenses/by/4.0/).
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. Introduction
Papillomaviruses comprise an ancient and ubiquitous virus
amily that infects humans and other animals (Bravo and Félez-
ánchez, 2015). Human papillomaviruses comprise the largest
roup of papillomaviruses. There are over 200 different HPV geno-
ypes identiﬁed to date based on full genome sequencing (2012).
he majority of HPV subtypes are classiﬁed under the alpha- and
eta-HPV groups while a few other HPV subtypes have been classi-
ed under the gamma, mu and nu genera (Bernard et al., 2010; de
illiers et al., 2004). In general, alpha HPVs infect mucosal epithelia
hile beta HPVs infect external cutaneous epithelia. HPV infection
auses a range of benign conditions such as condyloma acuminata
genital warts), focal epithelial hyperplasia, common warts, plan-
ar warts and pigmented warts (Cubie, 2013; Doorbar et al., 2015).
nfection with HPV is usually transient and the majority of infec-
ions are cleared by the immune system (Stanley, 2012). However,
n the case of some HPVs, if infection becomes persistent this may
ead to tumour progression (Bodily and Laimins, 2011). Around
orty alpha HPVs infect the anogenital epithelium. Of these, up to ﬁf-
een genotypes are so-called “high-risk” HPVs (HR-HPVs) because
hey are associated with a range of cancers including cervical and
ther anogenital cancers and oropharyngeal cancers (Cubie, 2013).
PV type 16 is the most prevalent HR-HPV responsible for 55% of
ervical cancers. After chlamydia, it is the second most prevalent
exually transmitted infectious agent worldwide. In the developed
orld the incidence of certain anogenital and oropharyngeal can-
ers has increased signiﬁcantly over the last decade (Gillison et al.,
015). Thus, the medical importance of HPV is clear. Vaccines
gainst HPV16 and HPV18, the next most prevalent HR-HPV and
he genital wart-causing, non-oncogenic HPVs 6 and 11, have been
vailable for eight years. However, these are prophylactic and can-
ot protect the very large numbers of people worldwide who are
lready infected and at risk of serious disease. Understanding viral
ene regulation and its relationship to the infected epithelium is a
ey goal to allow development of novel antiviral strategies in future.
. The human papillomavirus life cycle
.1. Human papillomavirus entry
Papillomaviruses have a small circular double-stranded DNA
enome of around 8 kb that is packaged in an icosahedral pro-
ein shell. The current model of the capsid is that it comprises 72
entamers of L1 protein, with L2 protein monomers inserted at
he centres of the pentamers (Buck and Trus, 2012). HPVs enter
asal cells of the cutaneous or mucosal epithelia through trauma
r microabrasions, but particularly in the cervical epithelium initial
nfection may  occur in the single cell layer between the ecto and
ndocervix (Herfs et al., 2012; Mirkovic et al., 2015) before trans-
er to the multi-layered epithelium. For most HPVs studied, the L1
apsid protein attaches to heparan sulphate proteoglycans on the
asement membrane or the basal epithelial cell surface and virus
nters into the cell by micropinocytosis (Sapp and Bienkowska-
aba, 2009). The entry receptors for HPVs are not fully understood
ut may  involve a number of proteins including epidermal growth
actor receptor (EGFR), integrins, tetraspanin-enriched membrane
icrodomains, laminins and the annexin-A2 heterotetramer (Raff . . .  . .  . . . . .  . . . .  . . . .  . . .  . . .  . . .  .  .  . . .  . . . .  .  . . . . . . .  . . . . .  .  . . .  . . . . . .  .  . .  .  .  .  .  . . . .  . . .  . . . 93
et al., 2013). HPV travels in the cytoplasm from endosomes to the
trans-golgi network and reaches the nucleus approximately 24 h
after initial attachment of virus. Recent evidence suggests that the
viral genome enters the nucleus following breakdown of the mem-
brane during mitosis (DiGiuseppe et al., 2016). Inside the nucleus,
initial ampliﬁcation of the virus genome to 50–100 copies occurs
through expression of E1 and E2 viral replication proteins (Ozbun,
2002). During division of infected cells, E2-binding proteins such
as cellular Brd4 can tether viral episomes to cellular chromatin
to allow equal segregation of viral genomes into daughter epithe-
lial cells (Wu  and Chiang, 2007). Upon basal cell division, infected
daughter cells may  stay in the basal layer or may  become transit
amplifying cells that begin to move into the suprabasal epithelial
layers (Doorbar, 2005).
2.2. Human papillomavirus replication and epithelial
differentiation
The HPV replication cycle is tightly linked to host cell differen-
tiation. The virus displays a tightly orchestrated gene expression
program that results in epithelium stratum-speciﬁc production of
viral proteins (Doorbar, 2005). The HPV genome can be categorized
into three parts: the long control region (LCR), the early region and
the late region (Fig. 1A). The LCR contains promoter sequences that
direct transcription of both the early and late genes (Bodily and
Laimins, 2011) and cis-acting sequences that regulate polyadenyla-
tion and viral late mRNA stability (Graham, 2008). Early mRNAs are
polyadenylated at the early polyadenylation site, while late mRNAs
are polyadenylated at one of two alternative polyadenylation sites
in the LCR (Milligan et al., 2007). Control of read-through of the
early polyadenylation site seems to constitute the major switch
signal from early to late gene expression (Johansson and Schwartz,
2013). The early region contains seven open reading frames that
encode the proteins E1, E2, E3, E4, E5, E6, E7, and E8, which carry
out regulatory functions. Only E6 and E7, and possibly E1 and E2
(there is insufﬁcient data to be sure of the sites of E8 expression
at present) proteins are truly early proteins that can be detected
in basal epithelial cells (Doorbar, 2005). E1, E2, E4, and E5 are
expressed in the suprabasal layers and can be considered inter-
mediate proteins. (Fig. 1B). In fact, maximum expression of the
E1 and E2 viral replication and transcription factors is found in
the mid  to upper epithelial layers (Coupe et al., 2012; Xue et al.,
2010). E4 protein is the ﬁrst, and most abundant, late protein to
be expressed in the mid  to upper layers of the epithelium in the
replicative stage of HPV infection (Doorbar et al., 1997; Middleton
et al., 2003) and it is likely that this is also the location of maxi-
mum  E5 expression (DiMaio and Petti, 2013). At least for HPV16,
the late structural proteins L1 and L2 that form the virus capsid
are expressed only in the ﬁnal stages of cellular differentiation in
the uppermost, granular layer of the epithelium where viral DNA is
packaged in the capsid to be released to infect other cells (Fig. 1B)
(Graham, 2010).
2.3. Interaction of HPVs with the epitheliumIn an uninfected epithelium, the suprabasal cells do not divide,
but undergo differentiation to eventually form the highly ker-
atinized squames that comprise the epithelial barrier to the
S.V. Graham, A.A.A. Faizo / Virus Research 231 (2017) 83–95 85
Fig. 1. A Schematic diagram of the HPV 16 genome. The double stranded DNA genome is shown as a gray shaded hoop. Numbers indicate positions on the genome. Promoters
P97, P670 and PE8 are indicated with chevrons. Oncogenes E6 and E7 are indicated as orange colored arcs, replication factors E1 and E2 are in red, regulatory proteins E4 and
E5  are in lilac and capsid proteins L1 and L2 are in green and blue arcs respectively. LCR (blue curved line), long noncoding region. pAE, position of the early polyadenylation
site.  pALs, position of the two  late polyadenylation sites (Milligan et al., 2007). B. Schematic diagram of the HPV16 life cycle in a differentiating epithelium. Viruses are show
as  light blue circles. Keratinocytes are in light orange color. Nuclei are colored pink. The basement membrane is drawn with a gray line. The key events in the virus replication
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Rycle  are indicated to the right hand side of the diagram of the epithelium together w
pithelium. Shading on the arrows represents the quantity of expression of each pr
nvironment (Taylor et al., 2009). HPV-infected epithelia also dis-
lay differentiation, but the process is somewhat abrogated by the
resence of the virus. In particular, expression of the viral E6 and
7 proteins in the lower to middle epithelial layers triggers the
ifferentiating cells of the suprabasal layers to re-enter S-phase.
lthough this misregulation would normally induce apoptosis, E6
rotein inhibits this process by degrading p53 (Bodily and Laimins,
011). Thus, the HPV-infected dividing cells of the mid  layers of the
pithelium can support viral DNA replication through recruitment
f an E2/E1 complex to the viral origin of replication. This in turn
ecruits the cellular DNA replication machinery (McBride, 2013).
eplication in the suprabasal layers generates many thousands of
opies of progeny HPV genomes. E4 seems to play a role in priming
he infected, differentiated epithelial cells to release newly formed
irions by restructuring cytokeratin ﬁlaments (Doorbar, 2013). It
ay  also contributed to genome ampliﬁcation and enhance virion
ynthesis (Doorbar et al., 2015). E5 is also expressed late in infec-
ion. Its various roles during the infectious life cycle have been
ifﬁcult to elucidate due to the very low levels of expression of this
mall protein. However, a major role of E5 is repression of MHC  pre-
entation of viral peptides to help avoid immune detection (DiMaio
nd Petti, 2013). Interactions with growth factor receptors EGFR
mainly HPVs) and PDGFR (mainly bovine papillomaviruses) indi-
ates that E5 can feed into, and modify, growth control and cell cycle
athways (DiMaio and Petti, 2013). Finally, in the granular layer of
he epithelium the L1 and L2 capsid proteins are produced.They
ncapsidate newly synthesized viral genomes to produce many
housands of progeny viruses which can initiate new infections
Fig. 1B) (Buck and Trus, 2012).
Owing to the complex interplay between the differentiating
pithelium and the HPV replication cycle, pathogenicity of HPV is
ikely due to speciﬁc regulatory interactions between viral proteins
nd host cells factors. Over the last decade, it has become clear that
NA processing factors especially splicing factors are an integral
art of these interactions and viral splicing control is the focus of
his review.. Splicing
The primary transcript (pre-mRNA) of a gene that emerges from
NA polymerase II upon transcription undergoes processing to schematic diagram of the gene expression program of the virus within the infected
subset during the virus replication cycle.
form a mature messenger RNA (mRNA). These processing events
occur co-transcriptionally and include capping, polyadenylation
and splicing (Moore and Proudfoot, 2009). Splicing is a basic cel-
lular process required for expression of the majority of metazoan
genes. During splicing, introns are removed from the primary tran-
script and the protein-coding exons are spliced together (Black,
2003). A macromolecular ribonucleoprotein complex called the
spliceosome carries out these reactions through recognition of 5′
and 3′-splice sites that mark exon/intron junctions in the pre-
mRNA, a “branch point” sequence, and a polypyrimidine tract
within the intron upstream of the 3′-splice site (Fig. 2A) (Wahl
et al., 2009). These sequences are the “landing pads” for the small
nuclear ribonucleoprotein particles (snRNPs U1, U2, U4, U5 and U6)
that make up the spliceosome that carries out the splicing reaction
(Wahl et al., 2009). Splicing occurs through a set of well-deﬁned
steps. First U1 snRNP bind to the 5′-splice site through comple-
mentarity between the snRNA of U1 snRNP and the splice site
itself, and the binding is stabilised through snRNP proteins such as
U1C. Next the branch point binds splicing factor 1 (SF1/BBP1), the
polypyrimidine tract binds U2AF65 while the 5′-splice site binds
its heterodimer partner, U2AF35. Next, SF1 is replaced upon the
branch point sequence by U2 snRNP whose binding is stabilised
by U2AF and the U4.U5.U6 tri-snRNP that joins the complex. U1
and U4 snRNPs are released and U2, U5 and U6 provide the active
site for splicing (Fig. 2A). The two-step enzymatic reaction involves
release of the upstream exon and lariat formation of the intron back
to the branch point followed by joining of the exons and release
and degradation of the lariat intermediate (Fig. 2B) (Papasaikas and
Valcárcel, 2016).
3.1. Control of splicing
The huge complexities of the splicing machinery facilitate splice
site recognition, but other regulatory mechanisms are important
for efﬁcient and accurate splice site detection. Exons contain cis-
acting sequences, called exonic sequence enhancers (ESEs), which
inﬂuence splicing efﬁciency. They do this by binding splicing
enhancing serine-arginine rich proteins (SR proteins). SR pro-
teins are conserved in eukaryotes and are present mainly in the
nucleus although some can shuttle to the cytoplasm (Busch and
Hertel, 2012). Very early in the splicing reaction U1 and U2 snRNP
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Fig. 2. A Basic features of a pre-mRNA recognised by the early splicing complex. Exons are shown as green boxes and intron the with a black line. Pink triangles indicate 5′-
and  3′- splice sites (ss). The intron branch point is indicated with A-OH. The 3′ intronic polypyrimidine tract is shown as Yn. U1 snRNP is shown as a light blue oval. U2 snRNP
is  shown as a light beige oval. The U4.U5.U6 tri-snRNP is shown as red/pink spheres. U2AF 65 and 35 kDa dimer is shown as a blue oval and a circle. B proteins complexes are
not  drawn to scale. The catalytic steps in splicing. Exons are shown as green boxes and the intron as a black line. Splice sites and branch point annotations are as above. In
the  ﬁrst step of the splicing reaction the 2′ OH of the branch point adenosine attacks and breaks the phosphodiester bond in the RNA backbone at the 5′ splice site and a
new  bond is created between the 5′ splice site and the branch point to form a lariat intermediate structure. The second step involves another exonucleolytic attack of the 5′
splice site −OH onto the 3′ splice site. The exons are spliced together and the intron lariat is discarded.
Fig. 3. Splicing control by SR proteins and hnRNPs. SR proteins can enhance splicing by aiding the formation and stability of splicing complexes. In this case, for splicing
enhancement, only interactions with U1 and U2 snRNPs are shown. However, SR proteins bound to exonic sequence enhancers (ESEs) can inﬂuence formation of the various
U-snRNP complexes that form during a splicing reaction (Howard and Sanford, 2015). hnRNPs bound to exonic sequence silencers (ESSs) can counteract the activities of SR
proteins  (Eperon et al., 2000). A possible route of terminal exon deﬁnition is also shown where SR proteins bind to a polyadenylation upstream sequence element (USE) and
create interactions from there to the upstream 3′ splice site to enhance U-snRNP recruitment (Howard and Sanford, 2015). Green boxes indicate exons. Light blue vertical
boxes  indicate ESEs. Dark blue vertical boxes indicate ESSs. Introns and 5′ and 3′ untranslated regions are indicated with a black line. Pink triangles indicate 5′- and 3′- splice
sites  (ss). U1 snRNP is shown as a light blue oval. U2 snRNP is shown as a light beige oval. U2AF dimer is shown as a blue circle. SR proteins are represented by pink spheres.
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 beige box indicated a polyadenylation USE in the 3′ untranslated region. A downw
arly splicing complexes can assemble across introns to direct the
pliceosome to the correct splice sites (Fig. 2). Early splice complex
ormation and stabilisation is controlled by SR proteins binding to
SEs. For example, interaction between SR proteins and U2AF35
tabilises U2 snRNP bound to the 3′ end of an intron. Cross-exon
r intron splicing complexes are cooperatively stabilised by inter-
ctions between U1 snRNP and U2AF and SR proteins (Fig. 3).
oreover, SR proteins are implicated in recruitment of multi-
le splicing factors during the process of spliceosome assembly
nd are key players in the catalytic steps of the splicing reaction
Howard and Sanford, 2015). For complex genomes, SR proteins
deﬁne” exons in pre-mRNAs to establish exon-intron boundaries.
R proteins bound to ESEs connect the 3′ splice site at the 5′ end
f an exon with the 5′ splice site at the other end of the intron
nd mark the sequence as an exon for retention in the mRNA
Fig. 3). They also facilitate deﬁnition and splicing of terminal
xons (Howard and Sanford, 2015; Long and Caceres, 2009). They
ccomplish this by binding directly, or interacting with other RNA
rocessing factor complexes tethered in the mRNA 5′ untranslated
egion or the 3′ polyadenylation region, to provide a “feedback”
nteraction with the ﬁrst 5′-splice site or terminal 3′-splice site
espectively in the pre-mRNA (Fig. 3) (Berget, 1995; Proudfoot,
000).In addition to SR proteins, the exon/intron architecture, steric
indrance and RNA secondary structure may  also play a role in
irecting the activities of the spliceosome (De Conti et al., 2013).d CstF polyadenylation complexes are represented as light and dark orange spheres.
lack arrow indicates the polyadenylation site.
3.2. Alternative splicing
In constitutive splicing all introns are removed from the pre-
mRNA and every exon is present in the mature mRNA. Accurate
and speciﬁc recognition of correct 5′- and 3′-splice sites is essen-
tial to ensure production of the appropriate set of mRNAs in a cell
(Black, 2003). However, although consensus sequences have been
determined, 5′- and 3′-splice sites are frequently found to be degen-
erate. This ambiguity in splice site recognition gives rise to the
possibility of multiple choices of splice sites within complex pre-
mRNAs (Barash et al., 2010) (Roca et al., 2013). Indeed, we now
know that most mammalian pre-mRNAs can undergo regulated
selection of alternative 5′ and 3′-splice site. Alternative splicing
results in differential intron and exon retention, or skipping, or
choice of alternative (pseudo) splice sites to alter exon size, and
this process can generate several different mRNA and protein iso-
forms from each protein coding gene (Fig. 4) (Black, 2003; Irimia
and Blencowe, 2012; Ward and Cooper, 2010). The majority of alter-
native splicing events comprise “cassette” exon removal from a
pre-mRNA but mutually exclusive splicing is also common (Fig. 4).
Probably because the HPV genome is polycistronic, several types
of alternative splicing are used to generate HPV mRNAs. Cassette
exon removal is seen in the case of mRNAs that skip the E4 open
reading frame, e.g. E1Lˆ1 mRNAs. Read-through versus splicing also
occurs, e.g. E1Eˆ4,E5,L2,L1 versus E1Eˆ4Lˆ1 mRNAs. Alternative choice
of 3′ splice acceptor sites is seen in the case of the E6E7 RNAs. How-
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Fig. 4. A single gene can give rise to several alternative mRNAs. At the top is shown the structure of a hypothetical three-exon, two-intron gene. Exons are illustrated in green
and  introns and 5′ and 3′ untranslated regions as black lines. Two  alternative promoters Pwt and Palt are shown as forward facing black arrows. Two alternative polyadenylation
sites  (Poly(A)wt and Poly(A)alt) are shown as downward facing black arrows. An alternative (pseudo) 3′ splice site is indicated with a blue upward arrow. Some alternative
mRNA  structures that can arise from the hypothetical gene are shown. The three isoforms in the top row have undergone complete constitutive splicing. The three isoforms
in  the middle row are the products of alternative splicing of the gene. The bottom row shows the possible splicing patterns of a three exon gene where the middle so-called
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nal  mRNA isoforms produced.
ver, there is no evidence as yet for true mutually exclusive splicing.
lthough other cellular strategies exist by which different mRNA
soforms can be expressed from a single gene, including alternative
romoter usage and alternative polyadenylation (Fig. 4), alterna-
ive splicing makes the greatest contribution to maximising protein
roduction from the genomes of higher eukaryotes and viruses
Hernandez-Lopez and Graham, 2012; Ward and Cooper, 2010).
ollective studies have shown that most human pre-mRNAs nor-
ally undergo extensive alternative splicing. Over 90% of human
NAs are alternatively spliced and give rise to a cellular mRNA pop-
lation that can encode around 4–5 fold more proteins than there
re protein-coding genes in the genome (Hallegger et al., 2010).
lternative splicing is essential for development and differentia-
ion and organ function (Irimia and Blencowe, 2012). Mis-splicing
owever, is possible and it can give rise to serious health prob-
ems including cancers and genetic diseases (Scotti and Swanson,
016).
Control of alternative splicing is exerted by the strength of 5′
nd 3′-splice sites, the order in which exons emerge from RNA
olymerase II during transcription, the pattern of RNA process-
ng factors binding the pre-mRNA, the rate at which the gene is
ranscribed, and cell signaling. As mentioned above SR proteins
an act positively to control constitutive splicing, and this is also
rue for alternative splicing (Fig. 5). Splicing can be controlled
egatively by a large family of heterogeneous ribonucleoproteins
hnRNPs). hnRNPs can block exon/intron deﬁnition by interfer-
ng with assembly of the exon deﬁnition complex (Hertel, 2008).
herefore, the SR and hnRNP protein families can act antagonis-
ically in controlling splicing (Eperon et al., 2000). Apart from
SEs, other splicing regulatory cis-active signals exist: intronic
equence enhancers (ISEs) and exonic and intronic sequence
ilencers (ESSs, ISSs). SR proteins generally bind the enhancer
equences while hnRNPs bind the silencers. This sequence-speciﬁclusive splicing can take place. In this case either exon 2 or exon 3 is included in the
control of splicing has been termed the “splicing code” (De Conti
et al., 2013).
3.3. SR proteins
There are nine classical SR proteins (SRSF1-9) in addition to
other non-classical proteins such as SRp38 and Tra2  ˇ (SRSF10)
(Manley and Krainer, 2010). Each SR protein is composed of at least
one copy of each of two domains: 1) an RNA recognition motif and
2) a serine/arginine-rich domain (RS binding domain) (Long and
Caceres, 2009). As discussed above, in constitutive and alterna-
tive splicing SR proteins control recruitment of components of the
basic splicing machinery at exon-intron boundaries and mediate
exon/intron deﬁnition. SR proteins bound to ESEs can increase the
efﬁciency by which U-snRNPs detect splice sites, and this is par-
ticularly important if these sites are poorly conserved and liable
to be skipped by the splicing machinery (Fig. 5) Although SR pro-
teins usually act to enhance splicing, they have also been shown
to inhibit splicing. For example, SRSF9 can inhibit recognition of a
3′ splice site (leading to exon skipping) of exon 7 B in the hnRNP
A1 pre-mRNA through binding an ISS element (Simard and Chabot,
2002).
The functions of SR proteins are controlled by phosphorylation
of their RS domains. Several kinases are known to phosphory-
late SR proteins including Chk1, Topoisomerase (TOPO) 1 and
Serine/Arginine-protein kinases (SRPK) 1 and 2 (Giannakouros
et al., 2011). Phosphorylation is essential for SR protein func-
tions in constitutive and alternative splicing, but both hypo and
hyper-phosphorylated SR proteins can inhibit splicing (Zhou and
Fu, 2013) meaning that site-speciﬁc or temporal alterations in
phosphorylation must be a major point of control. The exact phys-
iological roles of phosphorylated forms of SR proteins are still to
be addressed. However, the suggested importance of SR protein
88 S.V. Graham, A.A.A. Faizo / Virus Research 231 (2017) 83–95
Fig. 5. SR proteins direct alternative splicing. The red central exon in this hypothetical gene is a “cassette” exon that can be omitted from one of the mRNA isoforms generated
from  the gene by a failure of the spliceosome to recognise the exon boundaries efﬁciently. A. The mRNA isoform product of splicing is the constitutive isoform because the
two  introns are spliced out and the three exons are spliced together. SR proteins binding to exonic sequence enhancers (ESEs: light blue vertical boxes) act in a dominant
positive manner to recruit U-snRNPs and/or increase efﬁciency of U-snRNP recognition of 3′ and 5′ splice sites and/or to antagonise the repressive activity of hnRNPs bound
to  exonic sequence silencers (ESS: dark blue vertical boxes). The number and range of SR proteins binding (usually) multiple ESEs on the exon can modulate the level of the
positive  effect. B. The mRNA isoform product of splicing is the alternative isoform because the central exon has not been recognised efﬁciently for splicing into the mRNA
and  only the two ﬂanking exons are spliced together. In this case hnRNPs bound to exonic sequence silencers may  exert repressive activity on U-snRNP recruitment and SR
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hosphorylation includes intracellular localization and trafﬁcking,
rotein–protein interactions and control of alternative splicing of
RNAs (Giannakouros et al., 2011; Long and Caceres, 2009).
SR proteins play a range of other roles in regulating gene
xpression including regulation of transcription elongation, mRNA
uclear export, stability and translation (Howard and Sanford,
015). Indeed, it seems likely that SR proteins may  have much
roader relevance to normal cellular metabolism than simply
heir role in splicing regulation. As documented for the paradigm
R protein SRSF1, other functions of SR proteins include chro-
atin remodelling, genome stability maintenance, nucleolar stress
esponse, cell cycle progression and apoptosis control (Das and
rainer, 2014). Current research has described some of the SR pro-
eins as oncogenic as they have been found to be overexpressed
n a range of cancers (Das and Krainer, 2014). Moreover several
ave been shown to possess oncogenic activity including SRSF1
ASF/SF2), SRSF2 (SC35), SRSF3 (SRp20) and SRSF9 (SRp30c) (Fu
t al., 2013; Jia et al., 2010; Karni et al., 2007; McFarlane et al., 2015).
ncogenic activity of SR proteins is due largely to their deregu-
ation of alternative splicing of RNAs whose protein products are
nvolved in key cellular pathways. In summary, increased SRSF lev-
ls can result in production of alternatively spliced RNA isoforms
hat encode key anti-apoptotic, cell proliferation and epithelial-
esenchymal transition (EMT)-inducing proteins (Das and Krainer,
014).
.4. hnRNP proteins
The hnRNP family is larger and more complex than the SR pro-
ein family. In humans, there are thirteen hnRNP protein families
ach of which contain several subtypes (Busch and Hertel, 2012).
xact details of how hnRNPs control splicing are understood in only
 few cases. They can bind cooperatively, multimerize, and spread
long exons to repress assembly of the spliceosome across adjacent
ntrons (Fig. 3) (Busch and Hertel, 2012). In alternative splicing, they
ay  block snRNP binding to adjacent splice sites. Importantly, SR
roteins can antagonise the negative effects of hnRNP proteins on
plicing perhaps by steric hindrance of hnRNP/RNA protein inter-
ctions (Fig. 5) (Eperon et al., 2000).. Splicing of HPV RNAs
DNA viruses such as human papillomavirus (HPV) require con-
titutive and alternative splicing to generate mRNAs encodingtranslated regions are indicated with a black line. Pink triangles indicate 5′- and 3′-
 oval. SR proteins are represented by pink spheres. hnRNPs are indicated with lilac
the many essential proteins that are required to initiate, main-
tain and complete their life cycles. During HPV infection of the
epithelium at least twenty different mRNAs are expressed, some
of which are the products of alternative splicing (Baker and Calef,
1997; Chen et al., 2014; Chow et al., 1987a,b; Doorbar et al., 1990;
Isok-Paas et al., 2015; Ozbun and Meyers, 1997, 1998; Palermo-
Dilts et al., 1990; Stoler et al., 1992, 1989; Tan et al., 2012;
Toots et al., 2014; Wang et al., 2011). Transcript maps may  be
viewed at (https://pave.niaid.nih.gov/#explore/transcript maps).
SR and hnRNP proteins control viral RNA processing during infec-
tion (Graham, 2010; Johansson and Schwartz, 2013). A map  of
known HPV16 mRNAs is shown in Fig. 6. In addition to this
infection-related control, SR and hnRNP proteins are overexpressed
in HPV-associated cervical pre-cancers and cancers (Mole et al.,
2009a; Fay et al., 2009) and therefore have the potential to impact
HPV gene expression in tumorigenesis.
4.1. HPV gene expression and splicing
Most information on regulation of viral gene expression has
been gathered from studies on HPV16, or the most closely related
HPV, HPV31. Early in the HPV16 infectious life cycle, transcription
initiates from the viral early promoter located at P97, and poly-
cistronic mRNAs encoding E6 and E7 E1, E2, E8 E4 and E5 are
synthesized. (Fig. 6). There is extensive splicing in the E6E7 region
of the pre-mRNAs with at least four splice isoforms possible that
have been conﬁrmed in patient tissues (Chen et al., 2014; Schmitt
et al., 2011). E6 full length (E6ﬂ) is an unspliced transcript that
includes the E6 and E7 open reading frames. E6*I, E6*II and E6*X
(also termed E6Eˆ7 or E6*III) are mRNAs alternatively spliced from
one 5′-splice site to one of three alternative 3′-splice sites in the
primary transcript (Fig. 6). Two rare splice isoforms with alternate
5′-splice sites have also been detected in HEK293 cells transfected
with an E6E7 expression construct (Ajiro et al., 2012). There are four
splice isoforms produced from the E1E2 region of the genome, E1Eˆ2,
E1Eˆ2C, E8Eˆ1, E8Eˆ2C (Chen et al., 2014; Coupe et al., 2012; Milligan
et al., 2007; Schmitt et al., 2011). These use a splice donor at either
genome position 880 or 1302 and one of two  splice acceptors at
2582, and 2709 (Fig. 6).
At late times of infection the viral late promoter (P670) is acti-
vated (Bodily and Laimins, 2011) together with a promoter located
at the 5′ end of the E1 open reading frame termed the E8 promoter
(Straub et al., 2015) (Fig. 6). Despite the fact that the E8Eˆ2C protein
is an inhibitor of E2 in transcription and replication, this results
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Fig. 6. A. Diagram of the linearised HPV16 genome showing the nine open reading frames (colored boxes) the three characterised promoters (forward facing arrows) and the
early  and late polyadenylation sites (thick black vertical lines). B. Schematic diagram of the known HPV16 early mRNA splice sites (adapted from (Zheng and Baker, 2006)).
The  diagram does not indicate the 3′ ends of the RNAs listed and is not to scale. Orange colored boxes indicate E6E7 coding regions. Red/pink colored boxes indicate E1E2
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n  blue. SA, splice acceptor. SD, splice donor. Arrowheads indicate splice sites. Gray
n increased expression of the HPV replication/transcription fac-
ors E1 and E2 that initiate vegetative viral genome ampliﬁcation.
he viral capsid proteins are expressed from two classes of poly-
istronic transcripts transcribed from the late promoter. The ﬁrst
ne includes two splice events to give E1Eˆ4Lˆ1 mRNAs that are con-
idered to encode E4 and L1 proteins and the second one includes
nly the E1Eˆ4 splice event and read-through from the early region
o yield an E4, E5, L2, L1 polycistronic mRNA. The packed nature
f the HPV genome in terms of signal sequences that regulate
ranscription, splicing and polyadenylation suggests that control
f mRNA production is complex. Moreover, it is clear that alterna-
ive splicing plays a major role in generating the range of mRNAs
equired to encode viral proteins, and that viral splicing may  be
egulated in a differentiation-stage speciﬁc manner.
.2. SR proteins controlling HPV gene expression
The extent and complexity of alternative splicing required to
roduce HPV mRNAs suggests that SR and hnRNP proteins could
e key regulators of the HPV replication cycle. A large body of evi-
ence has been amassed detailing the SR and hnRNP proteins that
ontribute to HPV mRNA alternative splicing and we are beginning
o understand some of the controlling mechanisms.agram of the known HPV16 late mRNA splice sites (adapted from (Milligan et al.,
cheme is the same as for B. with the addition of L1 and L2 coding regions indicated
d lines, intron sequences.
4.2.1. E6 and E7 splicing
In the case of E6 and E7 RNA isoforms, the roles of SRSF1,
SRSF2 and SRSF3 have been investigated. In two studies, SRSF1
was not found to control E6E7 RNA splicing while depletion of
SRSF3 resulted in some reduction in E6E7 mRNA expression (Jia
et al., 2009; McFarlane et al., 2015). However, a very signiﬁcant
reduction in E6E7 RNA expression was observed in the absence of
SRSF2 (McFarlane et al., 2015). Although this splicing factor is a
major positive regulator of viral oncoprotein expression, the evi-
dence suggests that SRSF2 regulates E6E7 RNA stability rather than
splicing. Nonsense mediated decay is a mechanism whereby RNAs
such as the short E6E7 mRNAs, containing 3′-splice sites close to
stop codons are recognised as aberrant and subject to degradation
(Popp and Maquat, 2014). SRSF2 may be involved in E6E7 splicing
and protect the mRNA isoforms against decay. All of the E6E7 mRNA
isoforms were similarly affected in the above experiments. Of the
main E6E7 RNA isoforms, E6*I appears to be the most abundant
in tumour cells lines and in patient tissues (Schmitt et al., 2011;
Schmitt and Pawlita, 2011). E6*I mRNA may  encode an additional
viral protein expressed by HR-HPVs (Yuan et al., 2012) and in depth
studies have demonstrated that the putative E6*I protein appears
to have antagonistic properties to E6 itself. For example, E6*I can
promote apoptosis by counteracting E6ﬂ-mediated degradation of
p53 (Yuan et al., 2012). On the other hand, data from in vitro stud-
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atinocytes (Milligan et al., 2007) by promoting skipping of the E4
exon (Somberg et al., 2011). The L1 coding region contains an ESE0 S.V. Graham, A.A.A. Faizo / V
es has indicated that E6*1 mRNA may  allow translation of E7 by
einitiation on a downstream AUG (Stacey et al., 2000; Tang et al.,
006). In HPV16 infected keratinocytes, the balance of E6 ﬂ (intron-
ontaining) versus E6*I (intron removed) RNA isoform expression
as demonstrated to be regulated by EGF (Rosenberger et al., 2010).
GF signaling resulted in intron inclusion (SD226–SA409) to give
redominantly E6 ﬂ mRNAs while EGF depletion shifted the balance
owards intron splicing and E6*I production. In agreement with the
tudies mentioned above (Jia et al., 2010; McFarlane et al., 2015),
RSF1 did not play a role in regulating E6 alternative splicing. How-
ver, two transcription factors that can also control splicing, Brm
nd Sam68 were implicated. Brm is a component of the SWI/SNF
hromatin remodeler and is proposed to regulate splicing by con-
rolling the rate of RNA polymerase II elongation while Sam68 is a
ember of the STAR protein family that controls splicing through
ignal transduction. Interestingly, it was proposed that EGF lev-
ls in tumour cells might allow a switch to production of the E6*I
RNA isoform from which E7 protein would be more efﬁciently
ranslated via reinitiation at the E7 AUG. Increased E7 expres-
ion would ensure enhanced cell cycle progression, a hallmark of
PV-associated tumour progression (Roman and Munger, 2013).
onversely, in infected normal keratinocytes EGF signaling in the
asal epithelial cells would favour E6 full length production and
nhibition of apoptosis of the infected cell (Rosenberger et al., 2010).
inally, another study has shown that E6 isoform production from
PV18 is controlled by another transcription factor that can also
ave roles in transcription-linked splicing, CCCTC-binding factor
CTCF). CTCF binds to a motif in the E2 region of the HPV18 genome
nd initiates a pause in RNA polymerase II transcription that favours
orrect splicing of the E6E7 RNA. Deletion of the CTCF binding site
ithin the viral genome led to a signiﬁcant increase in levels of the
6 and E7 oncoproteins (Paris et al., 2015). It will be interesting in
uture to discover if there is any link between CTCF activity and EGF
ignaling.
.2.2. Early RNA splicing
Most viral early RNAs are spliced from a 5′-splice site at
ucleotide 880 in the E1 gene region to a 3′-splice site at nucleotide
358 to retain the E4 open reading frame (Fig. 6). The E4 gene does
ot contain a start codon but this is provided through splicing of the
egion encoding the ﬁrst ﬁve amino acids of E1 onto E4 (Roberts,
006). The 3′-splice site located at the 5′ end of the E4 open reading
rame is suboptimal due to lack of a good upstream polypyrimidine
ract meaning that it should be used at low efﬁciency (Kajitani and
chwartz, 2015). Despite this, the spliced transcript E1Eˆ4 that con-
ains the E4 open reading frame is the most abundant HPV mRNA
xpressed during an infection (Chen et al., 2014; Schmitt et al.,
011). Analysis of SR protein binding to the HPV16 E4exon has
hown that the 3′-splice site at nucleotide position 3358 (SA3358)
s controlled by a complex ESE containing an in silico-predicted ten
lusters of SRSF1 binding motifs (Somberg and Schwartz, 2010).
n all, ﬁfteen SRSF1 binding sites were identiﬁed, and mutation of
hese resulted in a redirection of splicing from SA3358 to a down-
tream 3′-splice site at nucleotide position 5639 at the 5′ end of the
1 open reading frame (Fig. 6). A subsequent study revealed that the
ajority of the ESE activity was due to a single SRSF1 binding site
Li et al., 2013a). Similar motifs are predicted in very similar regions
f E4 open reading frames of low and high risk, mucosal and cuta-
eous HPVs suggesting a ubiquitous SRSF1-mediated mechanism
or controlling E4 splicing. In the absence of SRSF1 enhancement of
he 3358 3′-splice site, there was competition from the downstream
A5639 that is used to produce L1-encoding mRNAs (Somberg and
chwartz, 2010). These data suggest that SRSF1 controls use of
A3358 at the 5′ end of the E4 open reading frame and inhibits
ate mRNA production. SRSF1 also had a low level repressive effect
n the splice site at the 3′ end of E4 open reading frame (SA3632)esearch 231 (2017) 83–95
that would also result in inhibition of late mRNA splicing (Somberg
and Schwartz, 2010). These observations demonstrate the posi-
tive and negative effects that a single SR protein can exert on
mRNA splicing. SRSF3 also binds an ESE within the E4 open read-
ing frame and enhances splicing at SA3358. Moreover, SRSF3 could
also inhibit viral late mRNA expression but this time by stimu-
lating polyadenylation at the early polyadenylation site (Jia et al.,
2009).
Splicing of the various RNAs arising from transcription of the E1
and E2 genes has been reported but it is as yet unclear how these
splicing events are controlled. However, because the RNAs use a 5′-
splice site at genome position 880 or 1302 with one of two splice
acceptors at 2582 and 2709, selection of one site over another must
be a controlled event (Straub et al., 2015). Compared to E6E7 and
E4-containing RNAs these seem to be rare RNA species, which may
hamper their analysis.
4.2.3. Late RNA splicing
Analyses of the early splice isoforms and their regulation
were mostly carried out in tumour cells such as HeLa cells
that mimic  undifferentiated epithelial cells or in undifferentiated
keratinocytes. These cell systems only support HPV early gene
expression because keratinocyte differentiation is required for viral
late protein expression. To begin to examine how SR proteins con-
tribute to late mRNA production through alternative splicing our
laboratory used siRNAs to deplete SR proteins in HPV16-infected,
differentiated keratinocytes to discover which were responsible for
controlling capsid mRNA and protein expression. HPV capsid pro-
tein expression is readily detected in keratinocytes that maintain
wild type episomal HPV genomes (Klymenko et al., 2016). Among
SRSFs 1–3, 5, and 7, depletion only of SRSFs 1 and 3 caused a change
in L1 capsid protein expression. SRSF1 knock down resulted in only
a small reduction in L1 expression but SRSF3 knock down caused
a greater than 50% reduction in L1 levels in the cells. Conversely,
SRSF3 overexpression in an undifferentiated keratinocyte popu-
lation resulted in induction of L1 protein expression (Klymenko
et al., 2016). Analysis of the major spliced RNAs encoding the cap-
sid proteins revealed that SRSF3 was  required for production of
the spliced late E4Lˆ1 mRNA that encodes the L1 major capsid pro-
tein because a reduction in levels of SRSF3 caused a decrease in
E4Lˆ1 mRNA levels with a corresponding increase in the unspliced
L2L1 mRNA that encodes the L2 minor capsid protein (Klymenko
et al., 2016). In agreement with a previous study (Somberg and
Schwartz, 2010), SRSF1 also contributed to maintaining levels of
the E4Lˆ1 spliced mRNA, but had a much more signiﬁcant and
inhibitory effect on L2L1 RNA levels. The data implicate SRSF3 as a
key direct regulator of viral late gene expression in differentiating
keratinocytes.
SRSF9 (SRp30c) has also been implicated in enhanced splicing
of HPV16 late transcripts (Somberg et al., 2011). In undifferenti-
ated HeLa cells, SRSF9 inhibited splicing at SA3358 at the 5′ end
of the E4 open reading frame resulting in redirection of splicing
downstream to SA5639 at the 5′ end of the L1 open reading frame.
SRSF9 was  also shown to overcome suppression of SA5639 via
neutralisation of splicing silencers in the L1 open reading frame
(Somberg et al., 2011) resulting in L1 RNA production. Finally, over-
expression of SRSF9 induced levels of a rare mRNA called L1i (E1Lˆ1)
(Somberg et al., 2011), which can be detected in differentiated ker-whose positive effect on splicing to SA5639 can be overridden by
hnRNP A1. While the proteins that bind are not yet elucidated they
could be an essential regulator of L1 mRNA splicing (Zhao et al.,
2007a).
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Table  1
RNA binding proteins and their effects on their target HPV16 RNAs. If it has been identiﬁed, the target splice acceptor (SA) or splice donor (SD) site is listed.
RNA binding protein Target RNA Effect Reference
SRSF1 E4 E4 LRE SA3358 enhancement
SD3632 suppression
Repression
Li et al. (2013a); Somberg and
Schwartz (2010)
Li et al. (2013a); Somberg and
Schwartz (2010)
McPhillips et al. (2004)
SRSF2 E6E7 Enhancement via
RNA stability
McFarlane et al. (2015)
SRSF3 E6E7 E4 Enhancement
SA3358 suppression
Jia et al. (2009); McFarlane
et al. (2015)
Jia et al. (2009, 2010)
SRSF9 E4 SA3358 suppression
SA5639 activation
Somberg et al. (2011)
Sam68 E6E7 E6exon inclusion Rosenberger et al. (2010)
Brm E6E7 E6exon inclusion Rosenberger et al. (2010)
hnRNPA1 E6E7 L1 LRE E6exon exclusion
SA5639 suppression
Repression
Rosenberger et al. (2010)
Zhao et al. (2007a); Zhao et al.
(2004); Zhao and Schwartz
(2007)
Chuen-Im et al. (2008)
hnRNPA2/B1 E6E7 E4 E6exon exclusion
Suppression/enhancement
Rosenberger et al. (2010)
Li et al. (2013b); Orrù et al.
(2012)
hnRNAPC1/C2 E4Early 3′UTR SD3632 enhancement
Activation/repression
Dhanjal et al. (2015)
Dhanjal et al. (2015)
hnRNPD E4 SD3632 suppression Dhanjal et al. (2015)
hnRNPH L2 Enhances early
polyadenylation
Öberg et al. (2003); Öberg et al.
(2005)
hnRNPI (PTB) Early 3′UTR Enhances early
polyadenylation
Relieves SD3632 suppression
Somberg et al. (2008); Zhao
et al. (2005)
Somberg et al. (2008)
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.3. hnRNP proteins controlling HPV gene expression
The hnRNP protein family has also been shown to control HPV16
RNA splicing. Both early and late mRNAs are under hnRNP con-
rol. Expression of the viral oncoproteins is controlled by hnRNP A1
hich activates splicing between the ﬁrst pair of splice sites (SD226
nd SA409) in viral E6E7 pre-mRNAs. As described above E6E7
RNA isoform expression is regulated by EGF-controlled alterna-
ive splicing (Rosenberger et al., 2010). EGF depletion is linked to
he activities of hnRNPs A1 and A2 and favours intron splicing lead-
ng to expression of the E6*I isoform (Rosenberger et al., 2010).
vidence also points to a role for hnRNP A1 in viral late mRNA
xpression. hnRNP A1 can bind AG-rich splicing silencer elements
n the HPV16 L1 coding region (Table 1) and counteract the activity
f SR proteins bound at L1 ESEs to suppress the use of the HPV16
ate 3′-splice site SA5639 (Zhao et al., 2007a; Zhao et al., 2004).
nRNP C1 appears to bind the viral early 3′ untranslated region
nd activate use of the 5′-splice site SD3632 at the 3′ end of the
4 open reading frame resulting in late mRNA production (Dhanjal
t al., 2015). Conversely, hnRNP D has been shown to bind to two
UAGUA motifs in an ESS element adjacent to SD3632 that controls
ate mRNA splicing (Li et al., 2013b). Indeed, it has been proposed
hat hnRNP C1, together with hnRNP D and hnRNP A2/B1, form a
omplex on this splicing silencer, but hnRNP C1 activity is dom-
nant and counteracts the hnRNP D and hnRNP A2/B1-mediated
SS-induced suppression of SD3632 leading to late mRNA splicing
Dhanjal et al., 2015; Li et al., 2013b). Polypyrimidine tract binding
rotein (PTB, hnRNP I) has also been reported to activate splicing
rom SD3632, perhaps by competing with the other hnRNP proteins
hat suppress use of this splice site (Somberg et al., 2008). hnRNP has been implicated in stimulating HPV16 early polyadenylation
hrough a G-rich enhancer element in the L2 coding region (Öberg
t al., 2005) and limiting viral late gene expression. hnRNP H couldolII-related control of
region alternative
g
Paris et al. (2015)
also antagonise viral late mRNA splicing, especially if it promoted
cooperative binding of hnRNP proteins on the L2L1 exons, but this
possibility remains to be investigated. Finally, hnRNPs E1, E2 and
hnRNP K were found to bind HPV16 L2 mRNAs. Although splicing
was not affected by these hnRNP proteins, they inhibited late mRNA
translation in in vitro studies (Collier et al., 1998).
4.4. Terminal exon deﬁnition
So far, no data exist on how the 5′-most exon in any HPV tran-
script is deﬁned. It is entirely possible that some of the proteins
already discovered to bind viral RNAs could play this sort of role
in splicing regulation. For example, for HPV16, proteins bound to
the cap, or 5′ untranslated region, of viral mRNAs could form a
cross-exon complex with the ﬁrst E6 exon/intron junction (SD226)
in transcripts synthesized from P97, or the E4 exon in transcripts
initiated from P670. More information is available regarding possi-
ble mechanisms of 3′ terminal exon deﬁnition, both for the early
mRNAs that terminate at the early polyadenylation, and those late
mRNAs that terminate at the late polyadenylation sites of HPV16.
The early polyadenylation site is inherently weak because the cis-
acting sequences that bind the CPSF and CstF polyadenylation
complexes are of poor consensus. However, polyadenylation com-
plex formation is strengthened by RNA binding proteins that form
a complex on a 57 nucleotide U-rich region in the early 3′ untrans-
lated region. Proteins that bind this region include hnRNP C1/C2,
PTB (hnRNP I) and the polyadenylation factors CPEB1 and hFip1
(Zhao et al., 2005). Recently, HPV E2 has also been shown to bind
the CPSF-CstF polyadenylation complex to reduce efﬁciency of HPV
early polyadenylation leading to transcription read-through to the
late region and production of viral late mRNAs (Johannson et al.,
2012). Since E2 can bind SR proteins including SRSF1 (Jang et al.,
2015; Muller et al., 2012), it is possible that E2 can deﬁne the early
9 irus R
t
p
e
a
s
l
p
o
t
(
l
i
p
m
c
a
e
i
t
2
i
f
5
a
l
l
i
l
(
f
m
2
o
p
2
t
e
s
5
m
t
s
f
l
i
I
j
i
s
P
s
a
t
s
l
t
r
l
u
2
t2 S.V. Graham, A.A.A. Faizo / V
erminal exon, E4, through an E2-containing polyadenylation com-
lex even if the complex has the potential of inhibitory activity for
arly polyadenylation. Moreover, E4 ESE sequences that bind SRSF1
re known to inﬂuence efﬁcient use of the early polyadenylation
ite (Rush et al., 2005; Somberg and Schwartz, 2010) thus high-
ighting the connection between terminal exon-bound proteins and
olyadenylation.
At the end of the L1 open reading frame, and spanning the start
f the late 3′ untranslated region, is a 79 nt RNA element termed
he negative regulatory element (NRE) or late regulatory element
LRE) (Graham, 2008). The element is a conserved feature of papil-
omaviruses (Zhao et al., 2007b), and inhibits late gene expression
n undifferentiated epithelial cells. For HPV16, it has been pro-
osed that the LRE may  enhance late polyadenylation, but another
echanism may  involve formation of an exon deﬁnition complex
omposed of U1 snRNP, U2AF and SRSF1 on the element. Such
 complex could mimic  a mini-intron and negatively regulate L1
xon deﬁnition (Furth et al., 1994; McPhillips et al., 2004). Interest-
ngly, the element also binds hnRNP A1 which might be expected
o counteract the activity of the SRSF1 complex (Chuen-Im et al.,
008). The effect of the balance between splicing stimulatory and
nhibitory factors in HPV mRNA terminal exon deﬁnition requires
urther investigation.
. HPV regulation of SR protein activity
Demonstrating their key roles in HPV infection, SR proteins
ppear to be upregulated during the HR-HPV life cycle in an epithe-
ial differentiation-speciﬁc manner. For example, SRSF1, 2 and 3
evels are signiﬁcantly increased in the mid  to upper layers of
nfected keratinocytes and in tissue samples from patients with
ow grade cervical lesions that represent transient HPV infection
Mole et al., 2009a). This is controlled by the HPV E2 transcription
actor (Mole et al., 2009a), which binds and trans-activates the pro-
oters of the SR protein genes (Klymenko et al., 2016; Mole et al.,
009b). The observed high levels of SR proteins in the nuclei of cells
f the mid  to upper layers of the infected epithelium correlate with
eak levels of E2 that are also detected in these cells (Coupe et al.,
012; Klymenko et al., 2016; Xue et al., 2010). It could be argued
hat E2 activation of SR proteins in the mid  to upper epithelial lay-
rs would be detrimental to viral replication. High levels of SRSF1
hould activate alternative splicing from SD880 to SA3358 at the
′ end of the E4 open reading frame, thus precluding expression of
RNAs encoding E2. It is possible that other SR proteins or hnRNPs
hat bind the E2 region of viral pre-mRNAs compete with E4 splice
ite selection to allow expression of E2, but E2 splicing regulatory
actors have not yet been reported. It is worth noting that very low
evels of E2 mRNAs compared to E4 mRNAs are detected in HPV-
nfected patient tissues (Schmitt et al., 2010; Chen et al., 2014).
n alternative splicing the rule seems to be that for mRNAs sub-
ect to alternative splicing, the ﬁrst pair of 5′- and 3′- splice sites
ntron that emerge from RNA polymerase II are preferentially cho-
en for splicing over subsequent sites. Thus, in mRNAs initiating at
670 of HPV16 the intron between SD880 and SA2582 or SA2709
hould be removed in preference to the intron between SD880
nd SA3358. Leaky splicing control could result in read-through
o the E4 splice site and competition between architecture (ﬁrst-
plice-ﬁrst) and a dominant E4 ESE could yield the observed low
evels of E2 mRNAs and high levels of E4-encoding mRNAs. E2 con-
rol of SR proteins could be beneﬁcial to completion of the virus
eplication cycle. SR protein expression is greatest in basal epithe-
ial layers but expression levels decrease to a low level in normal,
ninfected, differentiated keratinocytes (Fay et al., 2009; Jia et al.,
010; Mole et al., 2009a). This change is expected because differen-
iated epithelial cells are beginning to shut down nuclear functionsesearch 231 (2017) 83–95
such as splicing. However, in infected, differentiated keratinocytes
the viral late proteins such as E4 and L1 are express from spliced
mRNAs. Therefore, HPV-mediated upregulation of key splicing fac-
tors, for example factors that bind the L1 ESE (Zhao et al., 2007a),
could facilitate efﬁcient and accurate splicing in the infected differ-
entiating epithelial cell. SRSF3 seems to be a key SR protein driving
late gene expression (Klymenko et al., 2016), but SRSF3 also regu-
lates other SR proteins and has been designated a master regulator
of splicing (Ajiro et al., 2016; Änkö et al., 2012). This means that HPV
up-regulation of SRSF3 could have quite global effects on constitu-
tive and alternative splicing in differentiated keratinocytes, even to
the extent of inducing a de-differentiation or pre-neoplastic phe-
notype. An intriguing possibility emerges that HPV E2 control of SR
protein expression during and infectious life cycle could contribute
to HPV-associated tumour progression.
5.1. E2 as a splicing factor
HPV E2 protein plays a crucial role in the HPV life cycle and
pathogenicity due to its involvement in viral genome replication,
transcription and segregation (McBride, 2013). It consists of three
functional regions, an N-terminus which is the transactivation
domain, a C-terminal DNA binding domain and a hinge region that
links the N- and C-termini (Hegde, 2002). The interactome of E2
proteins with cellular proteins has recently been analysed to give
a clearer insight into the wide range of E2 activities (Janget al.,
2015; Muller and Demeret, 2012). E2 can interact with SR pro-
teins SRSF1, 2, 4, 5 and 7 (Bodaghi et al., 2009; Jang et al., 2015;
Lai et al., 1999; Muller and Demeret, 2012). E2 protein also inter-
acts with key components of the spliceosome and other cellular
RNA processing factors (Graham, 2016). While early studies on the
low risk HPV5 E2 serine-arginine-rich hinge domain showed that it
could facilitate splicing (Lai et al., 1999), a later study found that it
could not and suggested instead that HPV16 E2 may  have splicing
repressive activity (Bodaghi et al., 2009). This study also showed
that E2 can bind RNA directly via its C-terminal domain (Bodaghi
et al., 2009). E2 appears to have many of the properties of a protein
that can nucleate protein–protein and protein-RNA interactions.
Although further studies are required to elucidate the role of E2
in splicing regulation, it is clear that E2 protein could affect splic-
ing in the infected cell simply through its ability to recruit cellular
splicing factors to RNA in a similar manner to its recruitment of
polyadenylation factors (Johannson et al., 2012). Indeed, a study
using exon array analysis revealed that overexpression of E2 in
U2OS osteosarcoma cells resulted in signiﬁcant changes in cellular
alternative splicing (Gauson et al., 2014). This effect could be due
to E2 transcriptional upregulation of SR protein expression. How-
ever, increased SR protein levels were not observed in the study.
In fact, U2OS cells, like many cancer cell lines, already express high
levels of SR proteins (Graham, unpublished data) perhaps negating
the transcriptional trans-activation effect of E2. The most likely and
exciting explanation is that E2 alters regulation of cellular alterna-
tive splicing.
5.2. SR protein phosphorylation during infection
SR protein activity is controlled through phosphorylation by
serine-arginine protein kinases (SRPK) 1 and 2, Chk1 and Topoiso-
merase 1 (Zhou and Fu, 2013). Phosphorylation/dephosphorylation
cycles are crucial in splicing and nuclear export of SR proteins. As
well as SRSF proteins, SR protein kinases may also be regulated
during HPV infection. For example, HPV1 E4 colocalises with and
regulates SRPK1 in infected keratinocytes (Prescott et al., 2014).
E4 binding to SRPK1 alters its ability to phosphorylate SR proteins
in vitro suggesting that HPV infection can control not only SR pro-
tein levels, but also their various cellular activities (Prescott et al.,
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014). Another study made use of the adenovirus E4orf4 protein
o alter HPV16 mRNA production to favour production of the viral
4Lˆ1 spliced late mRNA (Somberg et al., 2009). E4orf4 interacts
ith SR proteins but can also bind the phosphatase PP2A. Indeed,
4orf4 overexpression in HeLa cells resulted in loss of SR protein
hosphorylation (Kanopka et al., 1998). Using HPV subgenomic
xpression plasmids in HeLa cells, it was found that overexpres-
ion of under-phosphorylated SR proteins induced viral splicing
o the major late 3′ splice site SD5639 and production of the late
4Lˆ1 mRNA (Somberg et al., 2009). The phosphorylation status
f SR proteins during HPV infection of the epithelium remains
o be studied in detail. At least for SRSF1, an increase in phos-
horylation was detected upon differentiation of HPV16-infected
12  cervical epithelial cells, but we have not yet determined
he downstream effects of this alteration on SRSF1 and the viral
ife cycle (McPhillips et al., 2004). Some drugs are available that
nhibit SRPK1. These small molecule inhibitors have been shown to
uccessfully inhibit replication of human immunodeﬁciency virus
HIV), hepatitis C virus (HCV) and Sindbis virus (Hernandez-Lopez
nd Graham, 2012). It will be informative to use these compounds
o investigate any effects on HPV splicing patterns.
. Conclusions
This review details many studies whose conclusions support
he hypothesis that cellular splicing regulatory mechanisms, and
plicing factors such as SR proteins and hnRNPs, are essential for
ontrolling HPV gene expression. Moreover, an emerging hypoth-
sis is that HPV infection controls cellular splicing in order to
omplete the viral life cycle in the differentiating epithelium. The
ecessary link between the HPV life cycle and epithelial differen-
iation must be considered important in elucidating mechanisms
egulating viral mRNA production. Activity of any RNA regulatory
lement should be responsive to the components of the protein
omplex that forms upon it. The positive and negative effects of the
arious RNA-binding factors on the multiple papillomavirus ele-
ents that regulate viral RNA processing could be altered during
he epithelial differentiation program due to changed levels of these
actors between undifferentiated and fully differentiated epithelial
ells. For example, in differentiated keratinocytes an HPV-induced
ncrease in levels of key SR proteins could alter the composition or
fﬁciency of formation of splicing complexes (or polyadenylation
omplexes) leading to appropriate late splicing events, stimula-
ion of late terminal exon deﬁnition and late polyadenylation. This
ould lead directly to efﬁcient viral late protein production in the
ppropriate (upper) epithelial layers.
Alternative splicing is essential for the life cycles of nuclear-
eplicating viruses because it allows expression of multiple proteins
rom a small genome. It is clear that alternative splicing is required
or the HPV replicative life cycle because it is only through alterna-
ive splicing that mRNAs encoding the E1 and E2 viral replication
actors are expressed, the correct balance of E6, E6 isoforms and
7 proteins are synthesized, and capsid protein synthesis is coor-
inated with epithelial differentiation. Alternative splicing is also
mplicated in HPV-associated cancer progression due to expression
f the various E6 mRNA isoforms that encode the viral oncoproteins
hose overexpression leads to tumorigenesis. Regulation of viral
ene expression at the level of alternative splicing still requires fur-
her study and number of important unanswered questions remain
o be addressed. For example, how does the architecture of the
arious viral pre-mRNAs allow alternative splicing given the pos-
ibility of steric hindrance between splicing complexes formed
t intron-exon junctions on short introns such as those found in
6E7 isoform RNAs? The viral late mRNAs contain unusually long
xons (L1 exon: 1.5 kb, L2L1 bicistronic exon: 2.9 kb) that likelyesearch 231 (2017) 83–95 93
contain pseudo-splice sites and alternative polyadenylation sites.
How are these exons deﬁned for accurate splicing? Some viral
mRNAs (e.g E6 ﬂ mRNA) are predicted to contain intronic sequences
which would normally preclude their nuclear export and trans-
lation. Other viruses express proteins that ensure efﬁcient export
of viral intron-containing transcripts (Harris and Hope, 2000) but
there is little information on how HPV ensures export of these
mRNAs. Further, the role of the HPV E2 protein, and its poten-
tial roles in regulating viral and cellular splicing, has yet to be
fully elucidated. Understanding HPV splicing could lead to devel-
opment of novel therapeutic approaches to inhibit viral replication
or virally-induced tumour formation in future (Graham, 2010;
Hernandez-Lopez and Graham, 2012).
Acknowledgements
A.A.A Faizo is supported by a PhD studentship from King Abdu-
laziz University, Saudi Arabia. We  acknowledge funding from the
Medical Research Council as core funding for the MRC  University
of Glasgow Centre for Virus Research. Studies in the Graham lab on
HPV life cycle and RNA processing were funded by the Wellcome
Trust, grant number WTd004098.
References
Ajiro, M.,  Jia, R., Zhang, L., Liu, X., Zheng, Z.-M., 2012. Intron deﬁnition and a branch
Site  adenosine at nt 385 control RNA splicing of HPV16 E6*I and E7 expression.
PLoS One 7 (10), e46412.
Änkö, M.-L., Müller-McNicoll, M.,  Brandl, H., Curk, T., Gorup, C., Henry, I., Ule, J.,
Neugebauer, K.M., 2012. The RNA-binding landscape of two SR proteins reveal
unique functions and bidning to diverse RNA classes. Genome Biol. 13, R17.
Ajiro, M.,  Jia, R., Yang, Y., Zhu, J., Zheng, Z.-M., 2016. A genome landscape of
SRSF3-regulated splicing events and gene expression in human osteosarcoma
U2OS cells. Nucleic Acids Res. 44 (4), 1854–1870.
Baker, C.C., Calef, C., 1997. Maps of Papillomavirus mRNA Transcripts. Los Alamos
National Laboratories, Los Alamos, NM USA, pp. III-3-III10.
Barash, Y., Calarco, J.A., Gao, W.,  Pan, Q., Wang, X., Shai, O., Blencowe, B.J., Frey, B.J.,
2010. Deciphering the splicing code. Nature 465 (7294), 53–59.
Berget, S., 1995. Exon recognition in vertebrate splicing. J. Biol. Chem. 270 (6),
2411–2414.
Bernard, H.U., Burk, R.D., Chen, Z., van Doorslaer, K., zur Hausen, H., de Villiers,
E.M., 2010. Classiﬁcation of papillomaviruses (PVs) based on 189 PV types and
proposals of taxonomic amendments. Virology 401, 70–79.
Black, D.L., 2003. Mechanisms of alternative pre-messenger RNA splicing. Annu.
Rev.  Biochem. 72, 291–336.
Bodaghi, S., Jia, R., Zheng, Z.-M., 2009. Human papillomavirus type 16 E2 and E6 are
RNA-binding proteins and inhibit in vitro splicing of pre-mRNAs with
suboptimal splice sites. Virology 386 (1), 32–43.
Bodily, J., Laimins, L.A., 2011. Persistence of human papillomavirus infection: keys
to  malignant progression. Trends Microbiol. 19 (1), 33–39.
Bravo, I.G., Félez-Sánchez, M.,  2015. Papillomaviruses: viral evolution, cancer and
evolutionary medicine. Evol. Med. Pub. Health 2015 (1), 32–51.
Buck, C., Trus, B., 2012. The papillomavirus virion: a machine built to hide
molecular achilles’ heels. In: Rossmann, M.G., Rao, V.B. (Eds.), Viral Molecular
Machines, Vol. 726. Springer, US, pp. 403–422.
Busch, A., Hertel, K.J., 2012. Evolution of SR protein and hnRNP splicing regulatory
factors. Wiley Interdiscip. Rev.: RNA 3 (1), 1–12.
Chen, J., Xue, Y., Poidinger, M.,  Lim, T., Chew, S.H., Pang, C.L., Abastado, J.-P., Thierry,
F.,  2014. Mapping of HPV transcripts in four human cervical lesions using
RNAseq suggests quantitative rearrangements during carcinogenic
progression. Virology 462–463, 14–24.
Chow, L., Reilly, S., Broker, T.R., Taichman, L., 1987a. Identiﬁcation and mapping of
human papillomavirus type 1 RNA transcripts recovered from plantar warts
and  infected epithelial cell cultures. J. Virol. 61 (6), 1913–1918.
Chow, L.T., Nasseri, M.,  Wolinsky, S.M., Broker, T.R., 1987b. Human papillomavirus
types 6 and 11 mRNAs from genital condylomata acuminata. J. Virol. 61 (8),
2581–2588.
Chuen-Im, T., Zhang, J., Milligan, S.G., McPhillips, M.G., Graham, S.V., 2008. The
alternative splicing factor hnRNP A1 is up-regulated during virus-infected
epithelial cell differentiation and binds the human papillomavirus type 16 late
regulatory element. Virus Res. 131, 189–198.
Collier, B., Goobar, L., Sokolowski, M.,  Schwartz, S., 1998. Translational inhibition
in vitro of human papillomavirus type 16 L2 mRNA mediated through
interaction with heterogeneous ribonucleoprotein K and poly (rC)-binding
proteins 1 and 2. J. Biol. Chem. 273 (35), 22648–22656.
Coupe, V.M., González-Barreiro, L., Gutiérrez-Berzal, J., Melián-Bóveda, A.L.,
López-Rodríguez, O., Alba-Domínguez, J., Alba-Losada, J., 2012. Transcriptional
9 irus R
C
D
D
d
D
D
D
D
D
D
D
D
E
F
F
F
G
G
G
G
G
G
H
H
H
H
H
H
H
I
I4 S.V. Graham, A.A.A. Faizo / V
analysis of human papillomavirus type 16 in histological sections of cervical
dysplasia by in situ hybridisation. J. Clin. Pathol. 65 (2), 164–170.
ubie, H.A., 2013. Diseases associated with human papillomavirus infection.
Virology 445 (1–2), 21–34.
as, S., Krainer, A.R., 2014. Emerging functions of SRSF1, splicing factor and
oncoprotein, in RNA metabolism and cancer. Mol. Cancer Res. 12 (9),
1195–1204.
e Conti, L., Baralle, M.,  Buratti, E., 2013. Exon and intron deﬁnition in pre-mRNA
splicing. Wiley Interdiscip. Rev.: RNA 4 (1), 49–60.
e Villiers, E.M., Fauquet, C., Broker, T.R., Bernard, H.U., zur Hausen, H., 2004.
Classiﬁcation of papillomaviruses. Virology 324, 17–24.
hanjal, S., Kajitani, N., Glahder, J., Mossberg, A.-K., Johansson, C., Schwartz, S.,
2015. Heterogeneous nuclear ribonucleoprotein C proteins interact with the
human papillomavirus type 16 (HPV16) early 3′-untranslated region and
alleviate suppression of HPV16 Late L1 mRNA splicing. J. Biol. Chem. 290 (21),
13354–13371.
iGiuseppe, S., Luszczek, W.,  Keiffer, T.R., Bienkowska-Haba, M.,  Guion, L.G.M.,
Sapp, M.J., 2016. Incoming human papillomavirus type 16 genome resides in a
vesicular compartment throughout mitosis. Proc. Natl. Acad. Sci. U. S. A. 113
(22), 6289–6294.
iMaio, D., Petti, L.M., 2013. The E5 proteins. Virology 445 (1–2), 99–114.
oorbar, J., Parton, A., Hartley, K., Banks, L., Crook, T., Stanley, M., 1990. Detection
of  novel splicing patterns in a HPV16-containing keratinocyte cell line.
Virology 178.
oorbar, J., Foo, C., Coleman, N., Medcalf, E., Hartley, O., Prospero, T., Napthine, S.,
Sterling, J., Winter, G., Grifﬁn, H., 1997. Characterisation of events during the
late stages of HPV16 infection in vivo using high-afﬁnity synthetic Fabs to E4.
Virology 238, 40–52.
oorbar, J., Egawa, N., Grifﬁn, H., Kranjec, C., Murakami, I., 2015. Human
papillomavirus molecular biology and disease association. Rev. Med. Virol. 25,
2–23.
oorbar, J., 2005. The papillomavirus life cycle. J. Clin. Virol. 32S, S7–S15.
oorbar, J., 2013. The E4 protein; structure, function and patterns of expression.
Virology 445 (1–2), 80–98.
peron, I.C., Makarova, O.V., Mayeda, A., Munroe, S.H., Caceres, J.F., Hayward, D.G.,
Krainer, A.R., 2000. Selection of alternative 5’ splice sites: role of U1 snRNP and
models for the antagonistic effects of SF2/ASF and hnRNP A1. Mol. Cell. Biol. 20
(2), 8303–8318.
ay, J., Kelehan, P., Lambkin, H., Schwartz, S., 2009. Increased expression of cellular
RNA-binding proteins in HPV-induced neoplasia and cervical cancer. J. Med.
Virol. 81 (5), 897–907.
u, Y., Huang, B., Shi, Z., Han, J., Wang, Y., Huangfu, J., Wu,  W.,  2013. SRSF1 and
SRSF9 RNA binding proteins promote Wnt  signalling-mediated tumorigenesis
by enhancing -catenin biosynthesis. EMBO Mol. Med. 5 (5), 737–750.
urth, P.A., Choe, W.-T., Rex, J.H., Byrne, J.C., Baker, C.C., 1994. Sequences
homologous to 5’ splice sites are required for the inhibitory activity of
papillomavirus late 3’ untranslated regions. Mol. Cell. Biol. 14, 5278–5289.
auson, E.J., Windle, B., Donaldson, M.M.,  Caffarel, M.M.,  Dornan, E.S., Coleman, N.,
Herzyk, P., Henderson, S.C., Wang, X., Morgan, I.M., 2014. Regulation of human
genome expression and RNA splicing by human papillomavirus 16 E2 protein.
Virology 468–470, 10–18.
iannakouros, T., Nikolakaki, E., Mylonis, I., Georgatsou, E., 2011. Serine-arginine
protein kinases: a small protein kinase family with a large cellular presence.
FEBS J. 278 (4), 570–586.
illison, M.L., Chaturvedi, A.K., Anderson, W.F., Fakhry, C., 2015. Epidemiology of
human papillomavirus–positive head and neck squamous cell carcinoma. J.
Clin. Oncol. 33 (29), 3235–3242.
raham, S.V., 2008. Papillomavirus 3’UTR regulatory elements. Front. Biosci. 13,
5646–5663.
raham, S.V., 2010. Human papillomavirus: gene expression, regulation and
prospects for novel diagnostic methods and antiviral therapies. Future
Microbiol. 5 (10), 1493–1505.
raham, S.V., 2016. Human papillomavirus E2 protein: linking replication,
transcription, and RNA processing. J. Virol. 90, 8384–8388.
allegger, M.,  Llorian, M.,  Smith, C.W.J., 2010. Alternative splicing: global insights.
FEBS J. 277, 856–866.
arris, M.E., Hope, T.J., 2000. RNA export: insights from viral models. Essays
Biochem. 36, 115–127.
egde, R.S., 2002. The papillomavirus E2 proteins. Annu. Rev. Biophys. Biomol.
Struct. 31, 343–360.
erfs, M.,  Yamamoto, Y., Laury, A., Wang, X., Nucci, M.R., McLaughlin-Drubin, M.E.,
Münger, K., Feldman, S., McKeon, F.D., Xian, W.,  Crum, C.P., 2012. A discrete
population of squamocolumnar junction cells implicated in the pathogenesis
of  cervical cancer. Proc. Natl. Acad. Sci. U. S. A. 109 (26), 10516–10521.
ernandez-Lopez, H.R., Graham, S.V., 2012. Alternative splicing in tumour viruses:
a  therapeutic target? Biochem. J. 445, 145–156.
ertel, K.J., 2008. Combinatorial control of exon recognition. J. Biol. Chem. 283,
1211–1215.
oward, J.M., Sanford, J.R., 2015. The RNAissance family: SR proteins as
multifaceted regulators of gene expression. Wiley Interdiscip. Rev.: RNA 6 (1),
93–110.rimia, M., Blencowe, B.J., 2012. Alternative splicing: decoding an expansive
regulatory layer. Curr. Opin. Cell Biol. 24 (3), 323–332.
sok-Paas, H., Männik, A., Ustav, E., Ustav, M., 2015. The transcription map  of
HPV11 in U2OS cells adequately reﬂects the initial and stable replication
phases of the viral genome. Virol. J. 12 (1), 1–15.esearch 231 (2017) 83–95
Jang, M.K.A., Anderson, D.E., van Doorslaer, K., McBride, A.A., 2015. A proteomic
approach to discover and compare interacting partners of papillomavirus E2
proteins from diverse phylogenetic groups. Proteomics 15, 13.
Jia, R., Liu, X., Tao, M.,  Kruhlak, M.,  Guo, M.,  Meyers, C., Baker, C.C., Zheng, Z.M.,
2009. Control of the papillomavirus early-to-late switch by differentially
expressed SRp20. J. Virol. 83 (1), 167–180.
Jia, R., Li, C., McCoy, J.P., Deng, C.X., Zheng, Z.M., 2010. SRp20 is a proto-oncogene
critical for cell proliferation and tumor induction and maintenance. Int. J. Biol.
Sci. 6 (7), 806–826.
Johannson, C., Somberg, M.,  Li, X., Winquist, E.B., Fay, J., Ryan, F., Pim, D., Banks, L.,
Schwartz, S., 2012. HPV-16 E2 contributes to induction of HPV-16 late gene
expression by inhibiting early polyadenylation. EMBO J. 31 (14), 3212–3227.
Johansson, C., Schwartz, S., 2013. Regulation of human papillomavirus gene
expression by splicing and polyadenylation. Nat. Rev. Micro. 11 (4), 239–251.
Kajitani, N., Schwartz, S., 2015. RNA binding proteins that control human
papillomavirus gene expression. Biomolecules 5 (2), 758.
Kanopka, A., Mühlemann, O., Petersen-Mahrt, S., Estmer, C., Öhrmalm, C.,
Akusjärvi, G., 1998. Regulation of adenovirus alternative RNA splicing by
dephosphorylation of SR proteins. Nature 393, 185–187.
Karni, R., de Stanchina, E., Lowe, S.W., Sinha, R., Mu,  D., Krainer, A.R., 2007. The
gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol.
Biol. 14 (3), 185–193.
Klymenko, T., Hernandez-Lopez, H., MacDonald, A.I., Bodily, J.M., Graham, S.V.,
2016. Human papillomavirus E2 regulates SRSF3 (SRp20) to promote capsid
protein expression in infected differentiated keratinocytes. J. Virol.
Lai, M.-C., Teh, B.H., Tarn, W.-Y., 1999. A human papillomavirus E2 transcriptional
activator. J. Biol. Chem. 274 (17), 11832–11841.
Li, X., Johansson, C., Cardoso Palacios, C., Mossberg, A., Dhanjal, S., Bergvall, M.,
Schwartz, S., 2013a. Eight nucleotide substitutions inhibit splicing to HPV-16
3′-splice site SA3358 and reduce the efﬁciency by which HPV-16 increases the
life  span of primary human keratinocytes. PLoS One 8 (9), e72776.
Li, X., Johansson, C., Glahder, J., Mossberg, A.-K., Schwartz, S., 2013b. Suppression of
HPV-16 late L1 5′-splice site SD3632 by binding of hnRNP D proteins and
hnRNP A2/B1 to upstream AUAGUA RNA motifs. Nucleic Acids Res. 41 (22),
10488–10508.
Long, J.C., Caceres, J.F., 2009. The SR protein family of splicing factors: master
regulators of gene expression. Biochem. J. 417 (1), 15–27.
Manley, J.L., Krainer, A.R., 2010. A rational nomenclature for serine/arginine-rich
protein splicing factors (SR proteins). Genes Dev. 24, 1073–1074.
McBride, A.A., 2013. The papillomavirus E2 proteins. Virology 445 (1–2), 57–79.
McFarlane, M.,  MacDonald, A.I., Stevenson, A., Graham, S.V., 2015. Human
papillomavirus 16 oncoprotein expression Is controlled by the cellular splicing
factor SRSF2 (SC35). J. Virol. 89 (10), 5276–5287.
McPhillips, M.G., Veerapraditsin, T., Cumming, S.A., Karali, D., Milligan, S.G., Boner,
W.,  Morgan, I.M., Graham, S.V., 2004. SF2/ASF binds the human papillomavirus
type 16 late RNA control element and is regulated during epithelial
differentiation. J. Virol. 78 (19), 10598–10605.
Middleton, K., Peh, W.,  Southern, S.A., Grifﬁn, H.M., Sotlar, K., Nakahara, T.,
El-Sherif, A., Morris, L., Seth, R., Hibma, M.,  Jenkins, D., Lambert, P., Coleman, N.,
Doorbar, J., 2003. Organisation of the human papillomavirus productive cycle
during neoplastic progression provides a basis for the selection of diagnostic
markers. J. Virol. 77 (19), 10186–10201.
Milligan, S.G., Veerapraditsin, T., Ahamat, B., Mole, S., Graham, S.V., 2007. Analysis
of  novel human papillomavirus type 16 late mRNAs in differentiated W12
cervical epithelial cells. Virology 360, 172–181.
Mirkovic, J., Howitt, B.E., Roncarati, P., Demoulin, S., Suarez-Carmona, M., Hubert,
P.,  McKeon, F.D., Xian, W.,  Li, A., Delvenne, P., Crum, C.P., Herfs, M.,  2015.
Carcinogenic HPV infection in the cervical squamo-columnar junction. J.
Pathol. 236 (3), 265–271.
Mole, S., McFarlane, M., Chuen-Im, T., Milligan, S.G., Millan, D., Graham, S.V., 2009a.
RNA splicing factors regulated by HPV16 during cervical tumour progression. J.
Pathol 219, 383–391.
Mole, S., Milligan, S.G., Graham, S.V., 2009b. Human papillomavirus type 16 E2
protein transcriptionally activates the promoter of a key cellular splicing
factor, SF2/ASF. J. Virol. 83 (1), 357–367.
Moore, M.J., Proudfoot, N.J., 2009. Pre-mRNA processing reaches back to
transcription and ahead to translation. Cell 136 (4), 688–700.
Muller, M.,  Demeret, C., 2012. The HPV E2-host protein–protein interactions: a
complex hijacking of the cellular network. Open Virol. J. 6, 173–189.
Muller, M.,  Jacob, Y., Jones, L., Weiss, A., Brino, L., Chantier, T., Lotteau, V., Favre, M.,
Demeret, C., 2012. Large scale genotype comparison of human papillomavirus
E2-host interaction networks provides new insights for E2 molecular
functions. PLoS Pathog. 8 (6), e1002761.
Öberg, D., Collier, B., Zhao, X., Schwartz, S., 2003. Mutational inactivation of two
distinct negative RNA elements in the human papillomavirus type 16 L2
coding region induces production of high levels of L2 in human cells. J. Virol. 77
(21), 11674–11684.
Öberg, D., Fay, J., Lambkin, H., Schwartz, S., 2005. A downstream polyadenylation
element in human papillomavirus type 16 L2 encodes multiple GGG  motifs
and interacts with hnRNP H. J. Virol. 79 (14), 9254–9269.
Orrù, B., Cunniffe, C., Ryan, F., Schwartz, S., 2012. Development and validation of a
novel reporter assay for human papillomavirus type 16 late gene expression. J.
Virol. Methods 183 (2), 106–116.
Ozbun, M.A., Meyers, C., 1997. Characterisation of late gene transcripts expressed
during vegetative replication of human papillomavirus type 31b. J. Virol. 71
(7), 5161–5172.
irus R
O
O
P
P
P
P
P
P
P
R
R
R
R
R
R
S
S
S
S
S
S
S
S
S
S
papillomaviruses. Virus Res. 125 (2), 135–144.S.V. Graham, A.A.A. Faizo / V
zbun, M.A., Meyers, C., 1998. Temporal usage of multiple promoters during the
life  cycle of human papillomavirus type 31b. J. Virol. 72 (4), 2715–2722.
zbun, M.A., 2002. Human papillomavirus type 31b infection of human
keratinocytes and the onset of early transcription. J. Virol. 76 (2), 11291–11300.
alermo-Dilts, D.A., Broker, T.R., Chow, L.T., 1990. Human papillomavirus type 1
produces redundant as well as polycistronic mRNAs in plantar warts. J. Virol.
64, 3144–3149.
apasaikas, P., Valcárcel, J., 2016. The spliceosome: the ultimate RNA chaperone
and sculptor. Trends Biochem. Sci. 41 (1), 33–45.
apillomavirus episteme: A comprehensive Papillomaviridae database and analysis
resource, 2012 https://pave.niaid.nih.gov/#explore/transcript maps.
aris, C., Pentland, I., Groves, I., Roberts, D.C., Powis, S.J., Coleman, N., Roberts, S.,
Parish, J.L., 2015. CCCTC-binding factor recruitment to the early region of the
human papillomavirus 18 genome regulates viral oncogene expression. J. Virol.
89 (9), 4770–4785.
opp, M.W.,  Maquat, L.E., 2014. The dharma of nonsense-mediated mRNA decay in
mammalian cells. Mol. Cells 37 (1), 1–8.
rescott, E.L., Brimacombe, C.L., Hartley, M.,  Bell, I., Graham, S., Roberts, S., 2014.
Human papillomavirus type 1 E1Eˆ4 protein is a potent inhibitor of the
serine-arginine (SR) protein kinase SRPK1 and inhibits phosphorylation of host
SR proteins and of the viral transcription and replication regulator E2. J. Virol.
88 (21), 12599–12611.
roudfoot, N., 2000. Connecting transcription to messenger RNA processing.
Trends Biochem. Sci 25, 290–293.
aff, A.B., Woodham, A.W., Raff, L.M., Skeate, J.G., Yan, L., Da Silva, D.M., Schelhaas,
M., Kast, W.M.,  2013. The evolving ﬁeld of human papillomavirus receptor
research: a review of binding and entry. J. Virol. 87 (11), 6062–6072.
oberts, S., 2006. The E4 protein- a late starter. In: Campo, M.S. (Ed.),
Papillomavirus Research: from Natural History to Vaccines and Beyond. Caister
Academic Press, Norfolk, England, pp. 83–96.
oca, X., Krainer, A.R., Eperon, I.C., 2013. Pick one, but be quick: 5′ splice sites and
the  problems of too many choices. Genes Dev. 27 (2), 129–144.
oman, A., Munger, K., 2013. The papillomavirus E7 proteins. Virology 445 (1–2),
138–168.
osenberger, S., Arce, J.D.-C., Langbein, L., Steenbergen, R.D.M., Rösl, F., 2010.
Alternative splicing of human papillomavirus type-16 E6/E6* early mRNA is
coupled to EGF signaling via Erk1/2 activation. Proc. Natl. Acad. Sci. U. S. A. 107
(15), 7006–7011.
ush, M.,  Zhao, X., Schwartz, S., 2005. A splicing enhancer in the E4 coding region
of  human papillomavirus type 16 is required for early mRNA splicing and
polyadenylation as well as inhibition of premature late gene expression. J.
Virol. 79 (18), 12002–12015.
app, M.,  Bienkowska-Haba, M.,  2009. Viral entry mechanisms: human
papillomavirus and a long journey from extracellular matrix to the nucleus.
FEBS J. 276 (24), 7206–7216.
chmitt, M.,  Pawlita, M.,  2011. The HPV transcriptome in HPV16 positive cell lines.
Mol. Cell. Probes 25 (2–3), 108–113.
chmitt, M.,  Dalstein, V., Waterboer, T., ClavelC. Gissman, L., Pawlita, M.,  2010.
Diagnosing cervical cancer and high grade precursors by HPV16 transcription
patterns. Cancer Res. 70 (1), 249–256.
chmitt, M.,  Dalstein, V., Waterboer, T., Clavel, C., Gissmann, L., Pawlita, M.,  2011.
The HPV16 transcriptome in cervical lesions of different grades. Mol. Cell.
Probes 25, 260–265.
cotti, M.M.,  Swanson, M.S., 2016. RNA mis-splicing in disease. Nat. Rev. Genet. 17
(1), 19–32.
imard, M.J., Chabot, B., 2002. SRp30c is a repressor of 3′ splice site utilization. Mol.
Cell. Biol. 22 (12), 4001–4010.
omberg, M.,  Schwartz, S., 2010. Multiple ASF/SF2 sites in the human
papillomavirus type 16 (HPV-16) E4-coding region promote splicing to the
most commonly used 3′-splice site on the HPV-16 genome. J. Virol. 84 (16),
8219–8230.
omberg, M.,  Zhao, X., Frõhlich, M.,  Evander, M.,  Schwartz, S., 2008. Polypyrimidine
tract binding protein induces human papillomavirus type 16 late gene
expression by interfering with splicing inhibitory elements at the major late 5’
splice site, SD3632. J. Virol. 82 (7), 3665–3678.omberg, M.,  Rush, M.,  Fay, J., Ryan, F., Lambkin, H., Akusjärvi, G., Schwartz, S.,
2009. Adenovirus E4orf4 induces HPV-16 late L1 mRNA production. Virology
383 (2), 279–290.
omberg, M.,  Li, X., Johansson, C., Orru, B., Chang, R., Rush, M.,  Fay, J., Ryan, F.,
Schwartz, S., 2011. Serine/arginine-rich protein 30c activates humanesearch 231 (2017) 83–95 95
papillomavirus type 16 L1 mRNA expression via a bimodal mechanism. J. Gen.
Virol. 92 (10), 2411–2421.
Stacey, S.N., Jordan, D., Williamson, A.J.K., Brown, M.,  Coote, J.H., Arrand, J.R., 2000.
Leaky scanning Is the predominant mechanism for translation of human
papillomavirus type 16 E7 oncoprotein from E6/E7 bicistronic mRNA. J. Virol.
74 (16), 7284–7297.
Stanley, M.A., 2012. Epithelial cell responses to infection with human
papillomavirus. Clin. Microbiol. Rev. 25 (2), 215–222.
Stoler, M.H., Wolinsky, S.M., Whitbeck, A., Broker, T.R., Chow, L.T., 1989.
Differentiation-linked human papillomavirus types 6 and 11 transcription in
genital condylomata revealed by in situ hybridisation with message-speciﬁc
RNA probes. Virology 172 (1), 331–340.
Stoler, M.H., Rhodes, C.R., Whitbeck, A., Wolinsky, S.M., Chow, L.T., Broker, T.R.,
1992. Human papillomavirus type 16 and 18 gene expression in cervical
neoplasia. Hum. Pathol. 23 (2), 117–128.
Straub, E., Fertey, J., Dreer, M.,  Iftner, T., Stubenrauch, F., 2015. Characterization of
the  human papillomavirus 16 E8 promoter. J. Virol. 89 (14), 7304–7313.
Tan, C.L., Gunaratne, J., Lai, D., Carthagena, L., Wang, Q.,  Xue, Y.Z., Quek, L.S.,
Doorbar, J., Bachelerie, F., Thierry, F., Bellanger, S., 2012. HPV-18 E2Eˆ4 chimera:
2  new spliced transcripts and proteins induced by keratinocyte differentiation.
Virology 429 (1), 47–56.
Tang, S., Tao, M.,  McCoy, J.P., Zheng, Z.-M., 2006. The E7 oncoprotein is translated
from spliced E6*I transcripts in high-risk human papillomavirus type 16- or
type 18-positive cervical cancer cell lines via translation reinitiation. J. Virol.
80  (9), 4249–4263.
Taylor, J.M., Street, T.L., Hao, L., Copley, R., Taylor, M.S., Hayden, P.J., Stolper, G.,
Mott, R., Hein, J., Moffatt, M.F., Cookson, W.O.C.M., 2009. Dynamic and physical
clustering of gene expression during epidermal barrier formation in
differentiating keratinocytes. PLoS One 4 (10), e7651.
Toots, M.,  Männik, A., Kivi, G., Ustav, M.,  Ustav, E., 2014. The transcription map  of
human papillomavirus type 18 during genome replication in u2os cells. PLoS
One 9.
Wahl, M.C., Will, C.L., Lührmann, R., 2009. The spliceosome: design principles of a
dynamic RNP machine. Cell 136 (4), 701–718.
Wang, X., Meyers, C., Wang, H.-K., Chow, L.T., Zheng, Z.-M., 2011. Construction of a
full transcription map  of human papillomavirus type 18 during productive
viral infection. J. Virol. 85 (16), 8080–8092.
Ward, A.J., Cooper, T.A., 2010. The pathobiology of splicing. J. Pathol. 220 (2),
152–163.
Wu,  S.-Y., Chiang, C.-M., 2007. The double bromodomain-containing chromatin
adaptor Brd4 and transcriptional regulation. J. Biol. Chem. 282 (18),
13141–13145.
Xue, Y., Bellanger, S., Zhang, W.,  Lim, D., Low, J., Lunny, D., Thierry, F., 2010. HPV16
E2  is an immediate early marker of viral infection, preceding E7 expression in
precursor structures of cervical carcinoma. Cancer Res. 70 (13), 5316–5325.
Yuan, C.-H., Filippova, M.,  Duerksen-Hughes, P., 2012. Modulation of apoptotic
pathways by human papillomaviruses (HPV): mechanisms and implications
for therapy. Viruses 4 (12), 3831.
Zhao, X., Schwartz, S., 2007. Inhibition of HPV-16 L1 expression from L1 cDNAs
correlates with the presence of hnRNP A1 binding sites in the L1 coding region.
Virus Genes 36 (1), 45–53.
Zhao, X., Rush, M.,  Schwartz, S., 2004. Identiﬁcation of an hnRNP A1-dependent
splicing silencer in the human papillomavirus type 16 L1 coding region that
prevents premature expression of the late L1 gene. J. Virol. 78 (20),
10888–10905.
Zhao, X., Oberg, D., Rush, M.,  Fay, J., Lambkin, H., Schwartz, S., 2005. A
57-nucleotide upstream early polyadenylation element in human
papillomavirus type 16 interacts with hFip1, CstF-64, hnRNP C1/C2 and
polypyrimidine tract binding protein. J. Virol. 79 (7), 4270–4288.
Zhao, X., Fay, J., Lambkin, H.,  Schwartz, S., 2007a. Identiﬁcation of a 17-nucleotide
splicing enhancer in HPV-16 L1 that counteracts the effect of multiple hnRNP
A1-binding splicing silencers. Virology 369, 351–363.
Zhao, X., Rush, M.,  Carlsson, A., Schwartz, S., 2007b. The presence of inhibitory RNA
elements in the late 3’-untranslated region is a conserved property of humanZheng, Z.-M., Baker, C.C., 2006. Papillomavirus genome structure, expression, and
post-transcriptional regulation. Front. Biosci 11, 2286–2302.
Zhou, Z., Fu, X.-D., 2013. Regulation of splicing by SR proteins and SR
protein-speciﬁc kinases. Chromosoma 122 (3), 191–207.
